

THE COMPANY


Corindus, A Siemens Healthineers Company, is a global technology leader in robotic-assisted vascular interventions. The company was founded in Israel in 2002 and relocated to the United States shortly thereafter. The company's headquarters can be found in Waltham, Massachusetts. Corindus employs approximately 120 people, primarily in Massachusetts, with

plans for significant growth this year as a result of the recent acquisition by Siemens Healthineers. The company has invested heavily in research and development to build next generation capabilities to transform care while expanding commercial capabilities to provide the benefits of vascular robotics to patients and hospitals.

ADVANCING
INTERVENTIONS
— WITH —
Vascular
Robotics

THE PRODUCT

CorPath GRX is the second-generation robotic system from Corindus. During a robotic-assisted intervention, the physician sits down in a radiation protected workstation and uses joysticks to manipulate devices that are held in a robotic arm located on the patient table. In the US, CorPath GRX is indicated for use by the FDA in coronary and peripheral vascular interventions and the company is working to expand its indication to include neurovascular interventions.



THE BENEFITS



Patients

- Robotic precision
- 1-millimeter positioning and sub-mm measurement of anatomy
- Potential to reduce radiation exposure²



Physicians

- Reduction in radiation exposure up to 95%¹
- No need to wear lead protective equipment, potential to reduce orthopedic burden
- Procedural control




Hospitals

- Robotic precision and procedural automation aimed at improving patient outcomes⁴
- Radiation protection for physicians and staff^{1,3}
- Market differentiation

THE VISION

Corindus is focused on developing innovative robotic solutions, such as remote robotics and advanced automation, to revolutionize treatment of emergent conditions such as heart attack and stroke. Remote robotics, or telerobotics, could potentially reduce time to treatment, provide greater access to highly skilled specialists and increase the number of treated patients, especially in stroke treatment. By incorporating additional advanced capabilities such as automation

and integration with imaging systems, the company also aims to standardize treatment algorithms, increase efficiency, and improve patient care.



References:

1. Weisz, G. et al. Safety and Feasibility of Robotic Percutaneous Coronary Intervention: PRECISE Study. J Am Coll Cardiol. 2013;61(15):1596-1600.
2. Smilowitz N, et al. Robotic-Enhanced PCI Compared to the Traditional Manual Approach. J Invasive Cardiol, 2014;26(7):318-321.
3. Campbell et al. Staff Exposure to X-ray during PCI: Randomized Comparison of

Robotic vs Manual Procedures. Presented at SCAI 2016.

4. Finn A, et. al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation. 2005;112:270-278

* Compared to levels found at the traditional table position during the PRECISE trial.

The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures.



Rx Caution: Federal law restricts this device to sale by or on the order of a physician.

